Lymphocytes regulate expression of the SARS‐CoV‐2 cell entry factor ACE2 in the pancreas of T2DM patients

Abstract

AbstractAimsCOVID‐19 patients with type 2 diabetes mellitus (T2DM) show both poorer clinical outcomes and have an increased risk of death. SARS‐CoV‐2 virus infection requires simultaneous expression of the SARS‐CoV‐2 cell entry factors angiotensin‐converting enzyme 2 (ACE2) and transmembrane protease serine type 2 (TMPRSS2) in the same cell. The aim of the study was to explore the underlying mechanisms of a COVID‐19 infection in patients with T2DM.MethodsThe distribution and expression of AEC2 and TMPRSS2 in different pancreatic cell types in clinical samples of T2DM patients and diabetic mouse models were analysed by single‐cell sequencing, bioinformatics analysis and basic experiments.ResultsThe results showed that ACE2 and TMPRSS2 are expressed in the ducts of the human pancreas. These findings suggest that SARS‐CoV‐2 can infect ductal cells in vivo through ACE2 and TMPRSS2. T2DM can promote the co‐expression of ACE2 and TMPRSS2 in exocrine ducts, including in the human pancreas. We hypothesize that ACE2 expression levels are associated with increased numbers of lymphocytes in vivo.ConclusionsIncreased blood glucose levels are associated with increased ACE2 expression and an increased number of lymphocytes. At the same time, lymphocytes can promote ACE2 expression.